Default.asp?SafetyInfoID=353
 mri_brain_scan
 Default.asp
 GenPg.asp?pgname=Disclaimer
 TheList_search.asp
 SafetyInfog.asp
 GenPg.asp?pgname=ScreeningForm
 GenPg.asp?pgname=ProductTesting
 GenPg.asp?pgname=OrderingBooks
 GenPg.asp?pgname=Lectures
 GenPg.asp?pgname=AboutDrShellock
 PriorityEmail.asp
 
 mri_brain_scan
 

                                            Safety Information Article
                      Information on this page is limited by the terms of our Disclaimer.  Please Read!

       Guidelines for the Management of Patients with Heart Valve Prostheses and Annuloplasty Rings Referred for MRI Procedures 

Guidelines for the Management of Patients with Heart Valve Prostheses and Annuloplasty Rings Referred for MRI Procedures

Frank G. Shellock, Ph.D., FACR, FISMRM, FACC
Adjunct Clinical Professor of Radiology and Medicine
Keck School of Medicine, University of Southern California
www.MRIsafety.com

In the clinical magnetic resonance imaging (MRI) setting, it is often necessary to manage patients with heart valve prostheses [including transcatheter aortic valve replacements (TAVR), transcatheter aortic valve implantation (TAVI) devices, percutaneous aortic valve replacement (PAVR) implants, transcatheter heart valves (THV), as well as other similar valve implants used in association with minimally invasive procedures] and annuloplasty rings (1-20).

MRI labeling information exists for many heart valve prostheses and annuloplasty rings. By following the pertinent MRI labeling information (i.e., presented in the Instructions for Use, Patient Identification Card, etc.), patients with heart valve prostheses and annuloplasty rings have safely undergone MRI examinations, including those performed at 1.5- and 3-Tesla (15, 20, 22). Notably, there has never been an adverse event reported in association with performing MRI in patients with these particular implants.

Unfortunately, the standard policy that MRI labeling information is required before allowing the use of MRI in a patients with heart valve prostheses and annuloplasty rings limits access to this important diagnostic imaging modality for those patients for which labeling information is unavailable. However, in consideration of the relevant peer-reviewed literature and other related documents (1-22), it is acceptable and safe to perform MRI examinations in all patients with heart valve prostheses and annuloplasty rings by following specific guidelines developed by taking into consideration possible safety concerns (i.e., magnetic field interactions and MRI-related heating) for these implants.

Notably, by adhering to these admittedly conservative MRI conditions, all patients with heart valves and annuloplasty rings can benefit from the diagnostic imaging information provided by one of the most important noninvasive imaging modalities.

Guidelines. The following guidelines apply to using MRI in all patients with heart valve prostheses and annuloplasty rings:

(1) Patients with all commercially available heart valve prostheses and annuloplasty rings can be scanned at 1.5-Tesla/64-MHz or 3-T/128-MHz, regardless of the value of the spatial gradient magnetic field.

(2) Patients with all commercially available heart valve prostheses and annuloplasty rings can undergo MRI immediately after placement of these implants.

(3) The MRI examination must be performed using the following parameters:

  • 1.5-Tesla or 3-Tesla, only
  • Whole body averaged specific absorption rate (SAR) of 2-W/kg, operating in the Normal Operating Mode for the MR system
  • Maximum imaging time, 15 minutes per pulse sequence (multiple sequences per patient are allowed)

Important Note: Any deviation from the above MRI conditions requires prior approval by a radiologist or supervising physician.

Important Note: These guidelines must be reviewed on an annual basis to confirm that no new heart valve prosthesis or annuloplasty ring has become available that substantially deviates from the above MRI conditions or that is labeled, MR Unsafe.

References

(1) Ahmed S, Shellock FG. Magnetic resonance imaging safety: Implications for cardiovascular patients. Journal of Cardiovascular Magnetic Resonance 2001;3:171-181.

(2) Edwards MB, Taylor KM, Shellock FG. Prosthetic heart valves: Evaluation of magnetic field interactions, heating, and artifacts at 1.5-Tesla. J Magn Reson Imag 2000;12:363-369.

(3) Frank H, Buxbaum P, Huber L, et al. In vitro behavior of mechanical heart valves in 1.5-T superconducting magnet. Eur J Radiol 1992;2:555-558.

(4) Hassler M, et al. Effects of magnetic fields used in MRI on 15 prosthetic heart valves. J Radiol 1986;67:661-666.

(5) Levine GN, et al. Safety of magnetic resonance imaging in patients with cardiovascular devices: An American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization. Circulation 2007;116:2878-2891.

(6) Maragiannis D, et al. Functional assessment of bioprosthetic aortic valves by CMR. JACC Cardiovasc Imaging 2016;9:785-93.

(7) Myers PO, et al. Safety of magnetic resonance imaging in cardiac surgery patients: Annuloplasty rings, septal occluders, and transcatheter valves. Ann Thorac Surg 2012;93:1019.

(8) Pruefer D, et al. In vitro investigation of prosthetic heart valves in magnetic resonance imaging: Evaluation of potential hazards. J Heart Valve Disease 2001;10:410-414.

(9) Randall PA, et al. Magnetic resonance imaging of prosthetic cardiac valves in vitro and in vivo. Am J Cardiol 1988;62:973-976.

(10) Saeedi M, Thomas A, Shellock FG. Evaluation of MRI issues at 3-Tesla for a transcatheter aortic valve replacement (TAVR) bioprosthesis. Magnetic Resonance Imaging 2015;33:497-501.

(11) Shellock FG. Biomedical implants and devices: Assessment of magnetic field interactions with a 3.0-Tesla MR system. J Magn Reson Imag 2002;16:721-732.

(12) Shellock FG. Prosthetic heart valves and annuloplasty rings: Assessment of magnetic field interactions, heating, and artifacts at 1.5-Tesla. Journal of Cardiovascular Magnetic Resonance 2001;3:159-169.

(13) Shellock FG, Morisoli SM. Ex vivo evaluation of ferromagnetism, heating, and artifacts for heart valve prostheses exposed to a 1.5-Tesla MR system. J Magn Reson Imaging 1994;4:756-758.

(14) Shellock FG, Shellock VJ. MRI Safety of cardiovascular implants: Evaluation of ferromagnetism, heating, and artifacts. Radiology 2000;214:P19H.

(15) Shellock FG. Reference Manual for Magnetic Resonance Safety, Implants, and Devices: 2016 Edition. Biomedical Research Publishing Group, Los Angeles, CA, 2016.

(16) Shellock FG, Shellock VJ. MRI Safety of cardiovascular implants: Evaluation of ferromagnetism, heating, and artifacts. Radiology 2000;214:P19H.

(17) Shellock FG. Biomedical implants and devices: Assessment of magnetic field interactions with a 3.0-Tesla MR system. J Magn Reson Imag 2002;16:721-732.

(18) Soulen RL. Magnetic resonance imaging of prosthetic heart valves [Letter]. Radiology 1986;158:279.

(19) Soulen RL, Budinger TF, Higgins CB. Magnetic resonance imaging of prosthetic heart valves. Radiology 1985;154:705-707.

(20) www.mrisafety.com, accessed 4/25/17

(21) Shellock FG, Crues JV. MR procedures: Biologic effects, safety, and patient care. Radiology 2004;232:635-652.

(22) Shellock FG, Woods TO, Crues JV. MRI labeling information for implants and devices: Explanation of terminology. Radiology 2009;253:26-30.

[*The “Guidelines for the Management of Patients with Heart Valve Prostheses and Annuloplasty Rings Referred for MRI Procedures should only be implemented for use after the careful review by the supervising radiologist or physician responsible for the MRI facility and adoption as a written policy.]



_____________________________________________________________________________________
  (c) 2017 by Shellock R & D Services, Inc. and Frank G. Shellock, Ph.D. All Rights Reserved. All copyrights and pertinent trademarks are owned by Shellock R & D Services, Inc. and Frank G. Shellock, Ph.D. No part of the MRISAFETY.COM web site may be reproduced, stored in any retrieval system, or transmitted in any form or by any means, physical, electronic or otherwise, without the prior written permission of Shellock R & D Services, Inc. or Frank G. Shellock, Ph. D. Request for permission to reproduce any information contained on the MRISAFETY.COM web site should be addressed to: frank.shellock@gte.net
Be sure to read our Disclaimer.